Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

| STATEMENT ( | OF CHANGES IN | I BENEFICIAL | OWNERSHIP |
|-------------|---------------|--------------|-----------|
|             |               |              |           |

| OMB APPROVAL             |     |  |  |  |  |  |  |  |  |
|--------------------------|-----|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0287    |     |  |  |  |  |  |  |  |  |
| Estimated average burden |     |  |  |  |  |  |  |  |  |
| hours per response:      | 0.5 |  |  |  |  |  |  |  |  |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person*  JANTZ DEREK                                 |  |               |        |  | 2. Issuer Name and Ticker or Trading Symbol PRECISION BIOSCIENCES INC [ DTIL ] |  |        |                  |  |   |                    |   | ationship<br>k all app<br>Direc  | ,   | ng Per               | rson(s) to Is                           |   |             |  |
|---|--|---------------|--------|--|--|--|--------|------------------|--|---|--------------------|---|--|---|----------------------|---|---|-------------|--|
|   |  | IOSCIENCES, I |        | 100                                    | 3. Date of Earliest Transaction (Month/Day/Year) 05/17/2021                    |  |        |                  |  |   |                    | X   | X Officer (give title below) Other (specify below)  Chief Scientific Officer   |   |                      |   |   |             |  |
| 302 E. PETTIGREW STREET, SUITE A-100  (Street)  DURHAM NC 27701  (City) (State) (Zip) |  |               |        |  | 4. If A  | 4. If Amendment, Date of Original Filed (Month/Day/Year)                       |        |                  |  |   |                    | 6. Indi<br>Line)<br>X   | -/   |   |                      |   |   |             |  |
|   |  | Table         | I - No | n-Deriva                               | tive S   | Secu   | rities | Acq              | uired  | , Dis   | posed of           | , or E  | Benef  | ficially  | Own                  | ed                                      |   |             |  |
| 1. Title of Security (Instr. 3)  2. Transact Date (Month/Day                          |  |               |        | Execution Date,                        |  | 3.<br>Transaction<br>Code (Instr. 8)  4. Securities Acqu<br>Disposed Of (D) (I |        |                  |  | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported |                    | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) |  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |                      |   |   |             |  |
|   |  |               |        |  |  |  |        | Code             | v  | Amount  | (A) (D)            | or Pi   | rice   | Transa  | ction(s)<br>3 and 4) |   |   | (iiisti. 4) |  |
| Common Stock 05/17/2  |  |               |        |  | 2021   |  |        | S <sup>(1)</sup> |  | 20,000  | D                  | \$  | 9.38(2)  | 4,0   | )32,279              |   | D |             |  |
|   | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |               |        |  |  |  |        |                  |  |   |                    |   |  |   |                      |   |   |             |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                                   | ivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any   |               |        | Transaction of Code (Instr. Derivative |  | 6. Date Exercisable and Expiration Date (Month/Day/Year)                       |        |                  | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Ins<br>3 and 4) |   | Dei<br>Ser<br>(Ins | Price of<br>rivative<br>curity<br>str. 5)                         | 9. Number<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 4) | Ownershi<br>Form:<br>Direct (D)<br>or Indirec<br>(I) (Instr. 4    | Ownership<br>Form:   | Beneficial<br>Ownership<br>t (Instr. 4) |   |             |  |
|   |  |               |        |  | Code   | v  | (A)    | (D)              | Date<br>Exercis  | sable   | Expiration<br>Date | Title   | of<br>Share  | es  |                      |   |   |             |  |

## **Explanation of Responses:**

- 1. The sale was effected to cover the taxes incurred with the Reporting Person's previous option exercise.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$9.21 to \$9.63. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

## Remarks:

/s/ Dario Scimeca, Attorneyin-Fact for Derek Jantz

05/19/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.